Literature DB >> 29395307

Tumor associated macrophages in gynecologic cancers.

Venkatesh Krishnan1, Bruce Schaar2, Supreeti Tallapragada3, Oliver Dorigo4.   

Abstract

The complex tumor microenvironment in gynecologic cancers plays a major role in modulating anti-tumor immune responses. The interaction of cancer cells with the diverse spectrum of immune effector cells has an important impact on the efficacy of standard chemotherapy and novel immunotherapy approaches. In this review, we specifically focus on the role of macrophages in ovarian, endometrial and cervical cancers. We discuss the origins of macrophages and their polarization state dictated by the microenvironment's cues. Within the tumor niche, tumor-associated macrophages (TAMs) promote tumor growth and mediate immune-suppression thereby effecting treatment responses. We outline clinical strategies that directly target TAMs, including inhibition of macrophage differentiation, prevention of the recruitment of monocytes to the tumor, enhancement of phagocytosis and immune checkpoint blockade.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical; Endometrial; Gynecologic cancers; Microenvironment; Ovarian; Tumor-associated macrophages

Mesh:

Year:  2018        PMID: 29395307     DOI: 10.1016/j.ygyno.2018.01.014

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  30 in total

Review 1.  Circulating Transcripts and Biomarkers in Uterine Tumors: Is There a Predictive Role?

Authors:  Christine De Bruyn; Thaïs Baert; Thierry Van den Bosch; An Coosemans
Journal:  Curr Oncol Rep       Date:  2020-01-29       Impact factor: 5.075

2.  Silencing YKL-40 gene can inhibit inflammatory factor expression and affects the effect of THP-1 cells on endometrial cancer.

Authors:  Qin Luo; Jiangtao Fan; Lili Li
Journal:  Arch Gynecol Obstet       Date:  2021-08-21       Impact factor: 2.344

3.  Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer.

Authors:  Kalika Kamat; Venkatesh Krishnan; Oliver Dorigo
Journal:  Br J Cancer       Date:  2022-06-24       Impact factor: 9.075

Review 4.  Endometrial cancer.

Authors:  Vicky Makker; Helen MacKay; Isabelle Ray-Coquard; Douglas A Levine; Shannon N Westin; Daisuke Aoki; Ana Oaknin
Journal:  Nat Rev Dis Primers       Date:  2021-12-09       Impact factor: 65.038

5.  Endometrial Tumour Microenvironment.

Authors:  Carlos Casas-Arozamena; Miguel Abal
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 6.  The Immune Microenvironment in Human Papilloma Virus-Induced Cervical Lesions-Evidence for Estrogen as an Immunomodulator.

Authors:  Jayshree R S
Journal:  Front Cell Infect Microbiol       Date:  2021-04-30       Impact factor: 5.293

7.  Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.

Authors:  Christopher B Morse; Mirna N Toukatly; Mark R Kilgore; Kathy J Agnew; Sarah S Bernards; Barbara M Norquist; Kathryn P Pennington; Rochelle L Garcia; John B Liao; Elizabeth M Swisher
Journal:  Gynecol Oncol       Date:  2019-02-23       Impact factor: 5.304

Review 8.  Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.

Authors:  Alia Ghoneum; Sameh Almousa; Bailey Warren; Ammar Yasser Abdulfattah; Junjun Shu; Hebatullah Abouelfadl; Daniela Gonzalez; Christopher Livingston; Neveen Said
Journal:  Semin Cancer Biol       Date:  2021-01-18       Impact factor: 15.707

Review 9.  Macrophage Polarization States in the Tumor Microenvironment.

Authors:  Ava J Boutilier; Sherine F Elsawa
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 6.208

Review 10.  Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance.

Authors:  Łukasz Zadka; Damian J Grybowski; Piotr Dzięgiel
Journal:  Cell Oncol (Dordr)       Date:  2020-06-02       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.